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X-linked hyper-IgM syndrome (XHIGM) is one type of primary immunodeficiency diseases, resulting from defects in the CD40
ligand/CD40 signaling pathways. We retrospectively analyzed the clinical and molecular features of 20 Chinese patients diagnosed
and followed up in hospitals affiliated to Shanghai Jiao TongUniversity School ofMedicine from 1999 to 2013.Themedian onset age
of these patients was 8.5 months (range: 20 days–21 months). Half of them had positive family histories, with a shorter diagnosis
lag.Themost common symptoms were recurrent sinopulmonary infections (18 patients, 90%), neutropenia (14 patients, 70%), oral
ulcer (13 patients, 65%), and protracted diarrhea (13 patients, 65%). Six patients had BCGitis. Six patients received hematopoietic
stem cell transplantations and four of them had immune reconstructions and clinical remissions. Eighteen unique mutations in
CD40L gene were identified in these 20 patients from 19 unrelated families, with 12 novel mutations. We compared with reported
mutation results and used bioinformatics software to predict the effects ofmutations on the target protein.Thesemutations reflected
the heterogeneity of CD40L gene and expanded our understanding of XHIGM.
1. Introduction
X-linked hyper-IgM syndrome (XHIGM; HIGM1; OMIM:
308230) is one type of primary immunodeficiency diseases
(PIDs), resulting from defects in the CD40 ligand/CD40 sig-
naling pathways leading to impairment of immunoglobulin
isotype switching in B cells and characterized by recurrent
infections in association with markedly decreased serum
IgG, IgA, and IgE levels but normal or elevated serum IgM
levels [1]. Patients with XHIGM usually develop symptoms
by the first or second year of life. Over 50% of patients have
chronic or intermittent neutropenia, often associated with
oral ulcers.Opportunistic infections, especiallyCryptosporid-
ium parvum and Pneumocystis jirovecii infections, are com-
mon and prominent clinical feature of the patients. Besides
the susceptibility to recurrent bacterial and opportunistic
infections, these patients are prone to autoimmune man-
ifestations, especially hematologic abnormalities, arthritis,
and inflammatory bowel disease. Furthermore, an unusual
susceptibility to liver, pancreas, or biliary tract tumours has
been reported [2].
CD40L is the disease-causing gene of XHIGM [3–7],
located in Xq26.3-Xq27.1 and containing five exons and four
intervening introns. The corresponding translated protein
CD154 (also called CD40L, gp39, TNFSF5, or TRAP) con-
tains 261 amino acids and is mainly expressed on acti-
vated mature T cells. Its receptor, CD40, is expressed on
a variety of cells, such as B cells, monocytes/macrophage,
dendritic cells, endothelial cells, and epithelial cells [8, 9].
CD40-CD154 interactions provide a costimulatory signal for
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T cell activation and can lead to B cell proliferation and
immunoglobulin class switching, affecting both cellular and
humoral immunity [10, 11]. Therefore, XHIGM belongs to a
combined immunodeficiency disease category.
XHIGM is the most common subtype of hyper-IgM
syndromes (affecting about 70% of the patients) [12]. More
subtypes of hyper-IgM syndromes have been gradually
revealed. Diseases resulting from mutations in AICDA (ID:
57379), CD40 (ID: 958), UNG (ID: 7374), NEMO (ID:
8517), or NFKBIA (ID: 4792) genes are all involved in the
CD154-CD40- NF-𝜅B pathways and affected the class switch
recombination (CSR), somatic hypermutation (SHM), or
germinal center formation and form the subtypes of hyper-
IgM syndromes. Mutations in the promoter of CD40L were
also found [13]. The heterogeneity of hyper-IgM syndrome
brings the challenge for diagnosis and accurate and reliable
molecular testing methods are needed.
With diagnosed patients accumulated, people began to
analyze the clinical features and mutation characteristics of
these patients since 1992 [14]. A CD40L mutation database
(http://structure.bmc.lu.se/idbase/CD40Lbase/index.php) has
been founded and updated [15]. Retrospective research
results of XHIGM patients in Europe [16], USA [17], Japan
[18], and Latin America [19] were published. However,
little information about Chinese XHIGM patients has been
reported. In this study, we collected clinical data of Chi-
nese XHIGM patients diagnosed and followed up in our
center, reviewed their clinical and immune features, therapy,
and response, and investigated the mutation characteristics,
intending to increase our knowledge of this disease and
finally improve the quality of life in these patients.
2. Methods
2.1. Patients. Patients in present study were first diagnosed in
hospitals affiliated to Shanghai Jiao Tong University School
of Medicine or referred from other hospitals and followed
up in Shanghai Children’s Medical Center (also affiliated to
Shanghai Jiao Tong University School of Medicine) during
1999–2013. A total of 28 candidate patients with HIGM
phenotype were recruited. The inclusion criteria were low
sera IgG and IgA (2 standard deviations below normal value
for age), normal or elevated serum IgM, and compatible
infectious events. Patients with secondary immunodeficiency
conditions such as HIV or congenital rubella infections,
immunosuppressive drug use, or neoplasms were excluded.
Then CD154 expression on active T cells was detected by flow
cytometry and sequences of CD40L gene were analyzed. A
total of 20 patients with XHIGM were finally identified.
2.2. Data Collection. An informed consent was obtained
from each patient’s parent or guardian before enrollment in
the study. Clinical data were collected from the patients’ med-
ical records, including initial clinical manifestation, onset
age, diagnosis age, parental consanguinity, family history of
immunodeficiency, recurrent infections, autoimmune dis-
eases ormalignancy diseases, vaccination and allergic history,
complication, laboratory tests (including immunoglobulin
level and lymphocyte subpopulations), and treatments. A
total of 5mL venous blood was collected from patients for
pathogen screening and gene sequencing.
2.3. Molecular and Genetic Diagnosis. Detection of CD154
expression on activated CD4+ T cells was performed by flow
cytometry (FACScan, Becton Dickinson, USA) using specific
fluorescent-labeled monoclonal antibodies according to the
method described previously [20].
Genomic DNA was isolated from heparinized peripheral
blood by using the DP319 kit (Tiangen Biotech Co. LTD.,
China). The individual exons of CD40L gene, including
exon-intron boundaries, were amplified by polymerase chain
reaction (PCR) as previously described [21]. The system
for PCR reaction contained 13.5 𝜇L ddH
2
O, 1 𝜇L primer
for each direction, and 8.5 𝜇L 2 × Taq PCR MasterMix
(containing 0.1 UTaq/𝜇L, 500 𝜇M dNTP, 20mM Tris-HCl
(pH 8.3), 100mM KCl, and 3mM MgCl2 (Tiangen Biotech
Co. LTD., China), with total volume 25𝜇L). Amplification
conditions were 95∘C for 10 minutes, then 40 cycles of 94∘C
for 30 seconds, 55∘C for oneminute, and 72∘C for 30 seconds,
followed by a final extension of 72∘C for 2 minutes. The PCR
products were electrophoresed in 1.5% agarose gel, purified,
and sequenced. Mutations were investigated by alignment
with standard sequence published in NCBI. We sequenced
CD40L genes in 50 Chinese controls. Human SNP databases
(dbSNP in NCBI and 1000 Genomes) were also searched to
confirm the detected mutations.
2.4. Analysis Tools. Data were analyzed by SPSS statistical
software (version 21.0, SPSS Inc., Chicago, IL). Median and
range were used to present the characters of focused variable.
Bioinformatics software PolyPhen-2 (http://genetics.bwh
.harvard.edu/pph2/) and MutationTaster (http://www.muta-
tiontaster.org/) were used to predict the effects of point
mutations.
3. Results
3.1. Demographic Characteristics. From 1999 to 2013, 20
patients from 19 unrelated families (P2 and P3 are cousins)
were diagnosed as XHIGM, considering the clinical mani-
festations, lab examination, family history, decreased CD154
expression, and the mutation of CD40L gene (Table 1). The
median onset age of these patients is 8.5 months (range:
20 days–21 months). And the median of diagnosis lag is 50
months (range: 5 months–15 years). Half of the patients had
positive family histories of previous sibling deaths at an early
age and the diagnosis lag in them was much shorter than that
in patients with negative family histories (31 ± 23 months
versus 85 ± 55 months, 𝑃 = 0.015). Positive family history
with early death in male members may help in diagnosis.
3.2. Clinical Manifestations. Themost common symptoms of
XHIGM patients were recurrent sinopulmonary infections
(18 patients, 90%), neutropenia (14 patients, 70%), oral ulcer
(13 patients, 65%), and protracted diarrhea (13 patients,
65%). Respiratory and gastrointestinal systems were more
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frequently affected. Skin (7 patients, 35%), bone and joint
system (4 patients, 20%), central nervous system (3 patients,
15%), and urinary system (2 patients, 10%) were also affected
(detailed in Table 1).
Themedian onset age of diarrhea was 12.0months (range:
20 days to 20 months). Among them, two patients (P10, P11)
were diagnosed with inflammatory bowel diseases (IBDs)
under enteroscopes, and Cryptosporidium was isolated from
the stool of P11. Fungus was isolated from the stool of P13.
Pathogens in other patients were not identified.
Six patients had BCGitis (Table 2). The median onset
time of adverse drug reactions was 2 months old (range: 50
days–7months). Twoof the patients received antituberculosis
medicine treatments and recovered. The other four patients
had severe local adverse events after BCG vaccinations,
presenting ulceration >10mm or suppurative lymphadenitis,
and received surgeries to drain. Among them, P12 was
reinfected by tubercle bacillus at 35months old and recovered
after antituberculosis drug therapy. Besides, another patient
P14 suffered pulmonary tuberculosis at 8.5 years old, with
restrictive pulmonary capacity and splenomegaly and lym-
phadenopathy.Thepatient received isoniazide and rifampicin
treatment unregularly for nearly one year and developed
tuberculous meningitis and died at 10 years old.
Some special manifestations deserved extra attention. P5
was infected by measles and developed subacute sclerosing
panencephalitis (SSPE). P11 had Cryptosporidium infection,
with protracted diarrhea and elevated liver enzyme. More-
over, this patient developed chronic kidney disease, pre-
senting oliguria, edema, acidosis, increased creatinine con-
centration, and decreased glomerular filtration rate (GFR),
lasting for over four months. Renal biopsy showed tubu-
lointerstitial lesions and the patient received dialysis. P9
also developed chronic kidney disease, with oliguria, albu-
minuria, hematuria, increased serum creatinine and urea
nitrogen concentration, and anemia for over three months.
He also exhibited electrolyte disturbance (hypocalcemia and
hyperphosphatemia) and convulsion. Ultrasound examina-
tion revealed diffuse kidney impairments.
3.3. Hematologic Findings. Anemia was found in seven
patients (Table 3). Among them, P10 and P11 had IBDs and
the chronic bloody purulent stools might partly cause the
anemia. P9 and P11 had chronic kidney disease which may
lead to renal anemia. P15 had pure red blood cell aplastic
anemia demonstrated by bone marrow biopsy. Neutropenia
was the most common hematologic complication, occurring
in 70% of the patients (14 patients), 11 of which complicated
with oral ulcer.
The median serum IgM concentration was 3.15 g/L
(range: 0.74–11.7 g/L). Seventeen patients had elevated IgM
levels and three patients had normal IgM levels. Serum IgG
levels were uniformly decreased. IgA levels were reduced in
the majority of patients.
Lymphocyte counts were generally normal. Three
patients (P5, P9, and P11) exhibit significantly decreased
CD4/CD8 ratio. They all had severe clinical symptoms and
the decreased ratio reflected the impaired cellular immunity.
P5 had measles infection, leading to SSPE, and died within
one year. P11 had Cryptosporidium infection, with prolonged
elevated liver enzyme and impaired renal functions. P9 also
had severe manifestation, complicated with chronic renal
failure.
3.4. Mutation Analysis. Eighteen unique mutations were
identified in 20 patients from 19 unrelated families (P2 and
P3 were cousins and they had the same mutation. Besides,
P12 and P16 had the same mutation). Among the 19 families,
we found 7 deletions, 6 missense mutations, 2 nonsense
mutations, 2 splice site mutations, and 2 insertions (Table 4).
The mutations were distributed throughout the entire gene,
affecting all the domain of the protein, and exon 5 was
the most frequently affected region (10/19, 52.6%). Detailed
descriptions and analysis were in the Discussion section.
3.5. Therapy and Prognosis. Five patients had died (Table 1).
P5 developed SSPE aftermeasles virus infection at 15 years old
and died within one year. P14 was infected bymycobacterium
tuberculosis and died of tuberculous meningitis at 10 years
old. P17 had severe diarrhea and pneumonia since 14 months
and died at 2 years old. P3 and P13 received hematopoietic
stem cell transplantations (HSCT) but suffered from severe
infections and died at 22months and 56months, respectively.
Three patients were lost in followups. The other twelve
patients were alive till now, with the median age of 8 years
old (range: 2–27 years old).
Fifteen patients (75%) received intravenous immuno-
globulin (IVIG) treatment (Table 1). Eight patients could
receive IVIG regularly (400mg/kg/month) after diagnosis as
HIGM. All of them were free of severe bacterial infections,
although three of them still had recurrent oral ulcers. Seven
patients could not receive full-dose IVIG regularly. Among
them, one patient (P14) died of tuberculosis infection. Two
patients still had recurrent bacterial infections (P2 had recur-
rent otitis media and perianal abscess. P12 had otitis media,
pneumonia, and fever every half month).Three patients were
lost in followup. The other five patients did not receive IVIG
therapy, including the two patients who died from measles
infection (P5) and severe diarrhea and pneumonia (P17).
Six patients received HSCTs and the median age at trans-
plantation was 6 years old. Four patients received hematopoi-
etic stem cells fromHLA-identical unrelated donors and they
had clinical remissions and were followed up frommonths to
6 years.The other two patients hadHLA-half identical sibling
donors and died from severe infections (Table 5).
4. Discussions
This study described the clinical features of Chinese XHIGM
patients. Respiratory and gastrointestinal systems were more
frequently affected. Skin, bone and joint system, central ner-
vous system, and urinary system were also involved. In this
study, two patients (P9 and P11) developed chronic kidney
diseases. Cardiovascular disease, infections, and nonsteroidal
anti-inflammatory drugs (NSAIDs) are accepted risk factors
for causing chronic kidney disease [22]. P9 was born with
6 Journal of Immunology Research
Table 2: BCG vaccination-induced adverse drug reactions (ADR) and mycobacterium infections in XHIGM patients.
Patients Ages Performances Treatments
P6 2m BCGitis (ipsilateral axillary lymphadenitis) Surgery
P7 2m BCGitis (ipsilateral axillary lymphadenitis) Surgery
P12
50 d BCGitis (ipsilateral axillary lymphadenectasis) Antituberculosis medicine (rifampicin, unregularly)
35m Pulmonary tuberculosis Antituberculosis medicine (isoniazide + rifampicin + VitB6),antibiotics
P16 7m BCGitis (ipsilateral axillary lymphadenitis) Surgery
P17 2m BCGitis (ipsilateral axillary lymphadenitis) Surgery
P19 3m BCGitis (ipsilateral cervical lymphadenectasis) Antituberculosis medicine
P14
8.5 y
Pulmonary tuberculosis,
restrictive pulmonary capacity,
splenomegaly and lymphadenopathy
Antituberculosis medicine (isoniazide + rifampicin, unregularly),
antibiotics, IVIG, thymosin
10 y Tuberculous meningitis Antituberculosis medicine (isoniazide + rifampicin, unregularly)
Note: IVIG: intravenous immunoglobulin.
congenital heart diseases (ventricular septal defect and patent
ductus arteriosus). P11 had ulcerative colitis and received
NSAIDs treatment. Both of the patients had severe recurrent
infections because of immunodeficiency. These complica-
tions might partly contribute to the kidney involvement in
these two patients. Few reports on XHIGM patients with
chronic kidney diseases have been published till now. We
should pay more attention to the urinary system function in
further followups.
Opportunistic infections, especially Cryptosporidium
parvum and Pneumocystis jirovecii infections, are common
and prominent clinical feature of XHIGMpatients [16, 17, 23].
Besides, infections caused by tubercle bacillus were detected
[16, 17, 19]. A number of PIDs are reported to be susceptible
to severe mycobacterial disease following vaccination
with BCG, including severe combined immunodeficiency
(SCID), chronic granulomatous disease (CGD), and
Mendelian susceptibility to mycobacterial diseases (MSMD).
Increased BCG infections are also reported in patients with
hyperimmunoglobulin E syndrome (HIES) and XHIGM,
with less prevalence and severity of BCG complications
compared with the PIDs mentioned above [24]. In a
European survey, only two of the 56 XHIGM patients present
with tuberculosis [16]. However, in our study concerning
20 XHIGM patients, we found six patients had BCGitis
during the first year of life. One of them was reinfected by
tuberculosis at 35 months old. One more patient suffered
pulmonary tuberculosis and tuberculous meningitis and
died at 10 years old. In another cohort study focusing on
Chinese patients, five (38%) of the 13 XHIGM patients
had lymphoid tuberculosis after BCG vaccination [25],
the relatively high incidence of which was very similar
to ours. An Indian research group also reported that two
patients with pulmonary tuberculosis and one patient with
disseminated BCGiosis were found in the cohort study
including seven XHIGM patients [26]. Global Tuberculosis
Report 2013 by WHO pointed out that India and China had
the largest number of tuberculosis cases, taking up to 26%
and 12% of the global total, respectively [27]. In both China
and India, BCG vaccine is given to every newborn after
birth to prevent tuberculous meningitis and disseminated
disease, while in Europe, where incidence and prevalence
of tuberculosis are low, less than half of the European
countries have nationally recommended BCG vaccination.
The differences in tuberculosis prevalence and BCG coverage
may partly contribute to the differences of mycobacteria
complications in XHIGM patients.
Some recent discoveries may help to elucidate the sus-
ceptibility to mycobacterial infections in XHIGM patients.
Hayashi’s results indicated that CD40-CD154 signaling
might be an important step in host immune response
against Mycobacterium avium infection [28]. Klug-Micu
et al. revealed that activation of monocytes via CD40L
resulted in a Vitamin D-dependent antimicrobial activity
against Mycobacterium tuberculosis [29]. IL12/23-IFN-𝛾 axis
is involved in defending against BCG infection [24, 30].
Jain et al. [31] demonstrated that activated T cells from
XHIGM patients produced markedly reduced levels of IFN-
𝛾 and failed to induce antigen-presenting cells to synthesize
IL-12. We should continue to observe the susceptibility to
tuberculous infections in XHIGM patients and be con-
cerned about the immunity affected by tuberculous infection.
Furthermore, we found two patients with varicella-zoster
virus infections, one patient with measles virus infections,
one patient with fungus infections, and one patient with
Cryptosporidium infection, which all indicated the defects in
cellular immunity.
Mutations of CD40L geneare highly heterogeneous [18–
20, 32]. CD40Lbase, which was last updated in 2011, con-
tained 250 public entries. Besides, moremutations onCD40L
gene were reported in other studies [19, 33]. Considering the
published results, the common type of mutations in CD40L
might be missense mutations, followed by deletion/insertion
mutations, nonsense mutations, and splice site mutations
(detailed in Table 6). In our results, missense mutations and
deletion/insertionmutationswere themain types, composing
about 3/4 of the mutations.
Some possible mutation hotspots have been identified.
Notarangelo et al. [15] pointed out that W140 represents
a mutational hotspot. In Lee’s study [32], four possible
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Table 6: Mutation types in CD40L gene.
Reports Year Number of mutations Missense (%) Nonsense (%) Deletion (%) Insertion (%) Splice site (%)
This study 2013 19 31.6 10.5 36.8 10.5 10.5
Nonoyama et al. [18] 1997 13 30.8 23.1 23.1 0 23.1
Seyama et al. [20] 1998 28 32.1 17.9 7.2 14.3 32.1
Lee et al. [32] 2005 61 18.0 24.6 21.3 11.5 24.6
Winkelstein et al. [17] 2003 54 22.2 18.5 24.1 11.1 24.1
CD40Lbase [46] 2011 221 31.7 23.5 17.2 10.4 16.3
Cabral-Marques et al. [19] 2014 26 34.6 26.9 11.5 7.7 11.5
hotspotswere identified thatwereThr254, IVS1+1 g>t, IVS3+1
g>a/t, and IVS4+1 g>c. In the CD40Lbase, mutations were
concentrated in some special positions; that is, mutations in
C218, T254, and W140 have been identified in more than 10
patients, respectively, till now.
In this study, we identified two splice site mutations (P4:
IVS2−1 g>a and P10: IVS4−2 a>g). Vargas-Herna´ndez et al.
[34] and Garc´ıa-Pe´rez et al. [35] separately reported a IVS3−1
g>a mutation, resulting in exon 4 skipping and a protein
with 21-amino acid truncation. Weller et al. [36] reported
an IVS2−1 g>t mutation, resulting in exon 3 skipping and
forming a protein consisting of 107 amino acids. In our study,
P4 mutated in 3󸀠-acceptor splice sites, the same positions as
the three cases, and it can be inferred that thismutation could
also result in the skipping of exon 3. For the mutation in P10,
it has been reported in 1994 [37].Mutation in the acceptor site
of intron 4 allowed utilization of a cryptic acceptor site and a
few base pairs downstream in exon 5 and led to 8-nucleotides
deletion in P10.
Six patients had missense mutations in this study. From
data published in CD40Lbase (updated to 2011), the most
frequent amino acid substitutions were Leu to Ser/Pro, Thr
to Met, Gly to Arg, and Ala to Asp/Glu. Thusberg and
Vihinen [38] reported that there were 10 invariant positions
corresponding to the amino acids W140, L161, G167, Y169,
Y172, L205, G226, G227, L231, and G257 in CD40L, according
to sequence alignment and calculation. Disease causing
mutations are typically located at conserved positions within
a protein family, since these positions are usually essential for
the structure and/or function of the protein [38]. In our study,
the mutation in P6 (Gly167Arg) was previously reported
in two Iranian patients [39]. Substitution from glycine to
arginine introduced a larger side chain group and a positive
charge, which would profoundly change structure and func-
tions of the protein. The mutation in P20 (p.Trp140Arg) was
reported as one of the “hotspots” and eleven patients in all
had been reported to have this mutation until now. Trp140 is
a large hydrophobic residue buried inside the protein while
arginine had a large hydrophilic side chain with positive
charge. The Trp140Arg substitution would obviously lead to
destabilization of the structure.
Four missense mutations were novel. Mutation in P14
(p.Leu205Ser) changed the conserved hydrophobic residue
into a hydrophilic residue. Proline was involved in the
mutations in P11 (p.Pro10Ser) and P17 (p.Ala208Pro). Proline
is the only amino acid forming a ring with the backbone
and bends the main chain of the protein in a characteristic
way. Proline is a known breaker of secondary structures.
The substitution in the two patients would profoundly change
structure and functions of the protein. A p.Ala208Asp muta-
tionwas identified in anXHIGMpatient and reported in 2002
[40].
Effects of the four novel point mutations were analyzed
by using bioinformatics software PolyPhen-2 [41] and Muta-
tionTaster [42]. PolyPhen-2 predicted probably damaging
effects to the protein with a score over 0.99, respectively.
MutationTaster predicts that mutations in P13, P14, and P17
were disease causing, with probability value over 0.98.
Two patients had nonsense mutations at codon 236 and
codon 218, both of which were already reported [18, 36, 43].
Cys218 was involved in formation of a disulfide bridge and
nonsense mutation (p.C218X) had been reported in at least
twelve XHIGM patients and one carrier, usually associated
with more severe clinical presentation.
Nine patients had insertion/deletion mutations,
all changing the reading frames and leading to large
changes of the protein structure. P12 and P16 were
from unrelated families and they had the same mutation
(g.2091 2094delTAGA, c.158 161delTAGA, p.Ile53fsX13).
This mutation had been reported in at least another 6
unrelated patients and was the fifth common mutation
position in the CD40Lbase. The 4 deleted nucleotides were
very close to the acceptor splice site of intron 1 and were
flanked by repeat sequences, suggesting that these mutations
might be caused by slipped mispairing mechanisms. The
frame shift deletion led to a premature stop codon within
the extracellular unique domain. P2 and P3 were cousins
and they had the same mutation (g.186delG). The deletion in
exon 1 led to a premature stop codon in the transmembrane
domain.
In conclusion, we retrospectively investigated the clin-
ical, immunological, and molecular features of 20 Chinese
XHIGM patients diagnosed and followed up in our center.
We identified 18 uniquemutations inCD40L in these patients,
with 12 novel mutations. Various mutations reflected the
heterogeneity of CD40L gene, and we should go further to
investigate the relationship between genotype andphenotype.
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